MAP2K7 and metastatic melanoma: Overall, primary resistance occurs in 40 to 65% of metastatic melanoma cases either treated with targeted therapies, i.e., BRAF/MEK inhibitors or ICI [64], highlighting the need for new therapeutic options [65].